XML 14 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Policies (Details) (USD $)
0 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 27, 2014
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock, par value (in dollars per share)   $ 0.01   $ 0.01   $ 0.01
Stock split, conversion ratio 0.0833          
Share-based compensation arrangement by share-based payment award, expiration period       10 years    
Stock-based compensation       $ 997,000 $ 168,000  
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options   1,000,000   1,000,000    
Unvested stock options, unrecognized compensation expense weighted average recognition period       1 year 4 months 24 days    
Stock options, granted (in shares)   23,250     494,417  
Stock options, fair value assumptions, risk free interest rate   1.66%        
Stock options, fair value assumptions, dividend yield   0.00%        
Stock options, fair value assumptions, expected life   4 years 5 months 1 day        
Stock options, fair value assumptions, historical volatility rate   82.00%        
Common stock rights issued (in shares)       115,065 840,928  
Deferred revenue   945,000   945,000   1,088,000
Foreign currency translation adjustment, net of tax   (45,000) 104,000 (11,000) (69,000) (45,000)
Foreign currency transaction gain (loss), realized (less than)       (100,000) 100,000  
Options, warrants and conversion rights, common stock callable and antidilutive (in shares)       5,524,030 3,727,541  
Accumulated Other Comprehensive Income
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Foreign currency translation adjustment, net of tax       (11,000) (100,000) (45,000)
Pharmacogenomic Services
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Deferred revenue   200,000   200,000   2,000,000
Diagnostic Tools
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Deferred revenue   700,000   700,000   900,000
CEO and CFO
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock options, unvested options, vesting period       3 years    
Stock options, fair value assumptions, exercise price (in dollars per share)   $ 4.32   $ 4.32    
CEO
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock rights issued (in shares)       83,333    
CFO
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Common stock rights issued (in shares)       55,000    
Selling, General and Administrative Expenses
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock-based compensation       $ 1,000,000 $ 200,000  
Minimum
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock options, unvested options, vesting period       1 year    
Maximum
           
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock options, unvested options, vesting period       3 years